{
      "shorten": 0,
      "risk of": 1,
      "calculated using": 2,
      "approved in": 3,
      "experience": 4,
      "database": 5,
      "pioneered by": 6,
      "chosen based on": 7,
      "clinical sign": 8,
      "persist after": 9,
      "promotes": 10,
      "fuels": 11,
      "generic name": 12,
      "do not": 13,
      "enforce": 14,
      "third generation": 15,
      "prescribed by": 16,
      "performed in": 17,
      "future research": 18,
      "has fewer": 19,
      "levels affected by": 20,
      "neurotoxic in": 21,
      "occur due to": 22,
      "\u6d89\u53ca": 23,
      "prescribe": 24,
      "managed via": 25,
      "seeps from": 26,
      "synthesized in": 27,
      "project to": 28,
      "published by": 29,
      "swelling": 30,
      "do not require": 31,
      "public health concern": 32,
      "encodes": 33,
      "minimized with": 34,
      "assessed through": 35,
      "classified by": 36,
      "digests": 37,
      "sometimes contain": 38,
      "novel delivery systems include": 39,
      "can lead": 40,
      "brand examples": 41,
      "may attenuate": 42,
      "impair": 43,
      "change during": 44,
      "restores": 45,
      "lead to": 46,
      "clearance": 47,
      "subtype": 48,
      "removed through": 49,
      "viscosity": 50,
      "balances": 51,
      "explains": 52,
      "\u4f5c\u4e3a": 53,
      "not studied in": 54,
      "shown to": 55,
      "identify": 56,
      "generic availability": 57,
      "more effective than": 58,
      "stored at": 59,
      "range from": 60,
      "\u614e\u7528\u4e8e": 61,
      "preferred in": 62,
      "hereditary in": 63,
      "generated in": 64,
      "specifically treat": 65,
      "decreases": 66,
      "enhances effects of": 67,
      "excreted via": 68,
      "ineffective against": 69,
      "use": 70,
      "may worsen with": 71,
      "may lack": 72,
      "selection criteria": 73,
      "are part of": 74,
      "designed in": 75,
      "crosses placenta": 76,
      "factor": 77,
      "convenient for": 78,
      "rarely given as": 79,
      "synergistic with": 80,
      "distributed in": 81,
      "a metric in": 82,
      "helps eliminate": 83,
      "monitored via": 84,
      "is hypersensitivity reaction to": 85,
      "should be used": 86,
      "can interact": 87,
      "staffed by": 88,
      "degrade over": 89,
      "mounted on": 90,
      "adjusted by": 91,
      "\u589e\u52a0": 92,
      "plays role in": 93,
      "risk increased by": 94,
      "advantages": 95,
      "prolongs": 96,
      "therapeutic use": 97,
      "reported by": 98,
      "has lower": 99,
      "recorded in": 100,
      "expiry date": 101,
      "diluted with": 102,
      "deficient in": 103,
      "aided by": 104,
      "is concern for": 105,
      "synthetic versions": 106,
      "treated for": 107,
      "may indicate": 108,
      "increased risk of": 109,
      "may induce": 110,
      "does not need": 111,
      "drawn before": 112,
      "replace": 113,
      "\u963b\u65ad": 114,
      "collect": 115,
      "assists": 116,
      "transmits": 117,
      "verified by": 118,
      "dries": 119,
      "decreases effect of": 120,
      "aligns": 121,
      "combines": 122,
      "site of action": 123,
      "monitors": 124,
      "categorizes": 125,
      "FDA black box warning": 126,
      "advises on": 127,
      "adhere to": 128,
      "damages": 129,
      "\u62ee\u6297": 130,
      "shown in": 131,
      "resistant to": 132,
      "overdose": 133,
      "works in": 134,
      "public health": 135,
      "may protect": 136,
      "are": 137,
      "provides": 138,
      "utilized by": 139,
      "participates in": 140,
      "decays into": 141,
      "should be taken": 142,
      "delivers": 143,
      "dosage form": 144,
      "prevalent in": 145,
      "not recommended in": 146,
      "method": 147,
      "more sensitive to": 148,
      "often safe in": 149,
      "confirms": 150,
      "finances": 151,
      "administered with": 152,
      "complications include": 153,
      "confused with": 154,
      "class": 155,
      "onset varies": 156,
      "high for": 157,
      "represses": 158,
      "variant of": 159,
      "close": 160,
      "publish": 161,
      "confer": 162,
      "do not modify": 163,
      "added to": 164,
      "sealed with": 165,
      "monitored for": 166,
      "solution appears": 167,
      "\u5e38\u89c1\u8bf1\u56e0": 168,
      "equipped with": 169,
      "diagnosis involves": 170,
      "\u9700\u8981": 171,
      "reviewed in": 172,
      "severity varies": 173,
      "manifestation": 174,
      "characteristic of": 175,
      "pharmacodynamics": 176,
      "\u83b7\u53d6": 177,
      "implies": 178,
      "recorded by": 179,
      "are essential for": 180,
      "antagonistic to": 181,
      "risk factor for": 182,
      "monitored by": 183,
      "can calm": 184,
      "granted by": 185,
      "read": 186,
      "informs": 187,
      "can develop": 188,
      "reverse": 189,
      "used before": 190,
      "categorized under": 191,
      "absorbed via": 192,
      "obtained through": 193,
      "bridge": 194,
      "compared to": 195,
      "\u91cd\u8981\u4e8e": 196,
      "expensive for": 197,
      "culminates in": 198,
      "are a class of": 199,
      "correlate with": 200,
      "indicated for": 201,
      "give": 202,
      "confirm": 203,
      "tailored to": 204,
      "respond better to": 205,
      "developed by": 206,
      "genetic forms involve": 207,
      "emitted by": 208,
      "oxidized in": 209,
      "peak in": 210,
      "effects": 211,
      "increases in": 212,
      "caused by": 213,
      "absorbed minimally": 214,
      "often comorbid with": 215,
      "focuses on": 216,
      "duration varies": 217,
      "enzyme": 218,
      "categorized as": 219,
      "can reduce": 220,
      "\u6d53\u5ea6\u53d6\u51b3\u4e8e": 221,
      "exacerbates": 222,
      "can result in": 223,
      "differs in": 224,
      "emerges": 225,
      "last for": 226,
      "quality control": 227,
      "prescribes": 228,
      "receptor selectivity": 229,
      "publishes": 230,
      "may absorb": 231,
      "sourced from": 232,
      "regulatory status": 233,
      "produces": 234,
      "are contraindicated in": 235,
      "are produced by": 236,
      "research field": 237,
      "parameter": 238,
      "popular among": 239,
      "cardiotoxicity": 240,
      "interpret": 241,
      "benefits": 242,
      "banned in": 243,
      "effect potentially enhanced by": 244,
      "eases": 245,
      "formulated with": 246,
      "lasts over": 247,
      "prompt": 248,
      "specialize in": 249,
      "dwell time": 250,
      "\u5c5e\u4e8e": 251,
      "\u8003\u8651\u7528\u4e8e": 252,
      "guide": 253,
      "function tests": 254,
      "exposed to": 255,
      "powered by": 256,
      "\u534a\u8870\u671f": 257,
      "binds to": 258,
      "recommended in": 259,
      "catalyze": 260,
      "difficult to": 261,
      "distributed through": 262,
      "integrate with": 263,
      "tracked using": 264,
      "loses": 265,
      "limited for": 266,
      "relieved with": 267,
      "is common": 268,
      "reduces": 269,
      "shows efficacy against": 270,
      "has": 271,
      "avoided by": 272,
      "patient education includes": 273,
      "organizes": 274,
      "should not be used with": 275,
      "fertilized by": 276,
      "grow in": 277,
      "caution with": 278,
      "help manage": 279,
      "regulated as": 280,
      "special population": 281,
      "encoded by": 282,
      "open": 283,
      "recalled for": 284,
      "scanned with": 285,
      "induce": 286,
      "made of": 287,
      "taken with": 288,
      "can affect": 289,
      "coverage": 290,
      "useful in": 291,
      "aid in": 292,
      "branch of": 293,
      "\u53ef\u80fd\u589e\u52a0": 294,
      "is enhanced by": 295,
      "alleviated by": 296,
      "risk for": 297,
      "altered in": 298,
      "classifies": 299,
      "also prevents": 300,
      "costlier than": 301,
      "metastasizes to": 302,
      "mature in": 303,
      "helps develop": 304,
      "additive effect with": 305,
      "\u7814\u53d1\u59cb\u4e8e": 306,
      "short-acting": 307,
      "safer for": 308,
      "aim to": 309,
      "mild": 310,
      "distinguishes": 311,
      "activated by": 312,
      "alternative in pregnancy": 313,
      "mark": 314,
      "recommend": 315,
      "evolve with": 316,
      "can have": 317,
      "occurs within": 318,
      "alternation recommended for": 319,
      "often include": 320,
      "also treats": 321,
      "crosses": 322,
      "send signals to": 323,
      "host": 324,
      "inhibit": 325,
      "black box warning for": 326,
      "harbor": 327,
      "often receive": 328,
      "kill": 329,
      "lacks": 330,
      "distorts": 331,
      "are alternatives to": 332,
      "hydrolyzes": 333,
      "face challenges in": 334,
      "supply": 335,
      "categorized by": 336,
      "example is": 337,
      "distributed to": 338,
      "is involved": 339,
      "broad-spectrum": 340,
      "performed with": 341,
      "signal": 342,
      "can be used with": 343,
      "\u5f71\u54cd": 344,
      "narrows": 345,
      "is crucial": 346,
      "administered": 347,
      "stimulated by": 348,
      "relax during": 349,
      "contribute to": 350,
      "carries risk": 351,
      "stimulates": 352,
      "must match": 353,
      "are regulated by": 354,
      "is sensitive": 355,
      "\u51cf\u8f7b": 356,
      "lack cross-reactivity with": 357,
      "lighten": 358,
      "is characterized by": 359,
      "integrates": 360,
      "inhibitor": 361,
      "filled with": 362,
      "can mask": 363,
      "side effects": 364,
      "treatment failure suggests": 365,
      "alternative for": 366,
      "\u5f15\u8d77": 367,
      "properties": 368,
      "useful for": 369,
      "recommended after": 370,
      "replaces": 371,
      "produced by": 372,
      "alternative to": 373,
      "affected in": 374,
      "deals with": 375,
      "is prevented": 376,
      "makes it": 377,
      "absorbs": 378,
      "paralyzes": 379,
      "lubricates": 380,
      "exists in": 381,
      "studied in": 382,
      "does not affect": 383,
      "decreases absorption of": 384,
      "\u6709": 385,
      "is risk factor for": 386,
      "is first-line for": 387,
      "interfere with": 388,
      "function in": 389,
      "draw": 390,
      "increased in": 391,
      "sometimes combined with": 392,
      "evade": 393,
      "for otologic drugs": 394,
      "often tested in": 395,
      "effectiveness depends on": 396,
      "efficacy": 397,
      "indicator for": 398,
      "dilates during": 399,
      "sometimes causes": 400,
      "excreted in": 401,
      "absorbed with": 402,
      "adapt for": 403,
      "reduces risk": 404,
      "counteracts": 405,
      "undergo": 406,
      "customize for": 407,
      "has subtype": 408,
      "varies by": 409,
      "may delay": 410,
      "prolonged by": 411,
      "indication": 412,
      "\u5206\u6790\u5305\u62ec": 413,
      "teaching point": 414,
      "manufacturing standards": 415,
      "introduced at": 416,
      "monitoring required": 417,
      "ripens": 418,
      "educational material": 419,
      "heals by": 420,
      "penetrate": 421,
      "more effective in": 422,
      "considers": 423,
      "used to treat": 424,
      "sold": 425,
      "spreads to": 426,
      "emphasize": 427,
      "preservative": 428,
      "increases susceptibility to": 429,
      "digested by": 430,
      "must meet": 431,
      "stored under": 432,
      "not effective against": 433,
      "relax": 434,
      "disturbs": 435,
      "can reverse": 436,
      "\u7597\u6548\u53d7": 437,
      "refresh": 438,
      "harmed by": 439,
      "neutralize": 440,
      "act against": 441,
      "can become": 442,
      "work by": 443,
      "seen in": 444,
      "mutations increase": 445,
      "target": 446,
      "white part": 447,
      "may inhibit": 448,
      "cost-effective": 449,
      "disrupts": 450,
      "\u68c0\u6d4b": 451,
      "peaks in": 452,
      "are measured in": 453,
      "first-generation includes": 454,
      "need more": 455,
      "are a": 456,
      "repaired with": 457,
      "at risk due to": 458,
      "analyzed via": 459,
      "impacts": 460,
      "\u7528\u4e8e\u8bc4\u4f30": 461,
      "often paired with": 462,
      "pollute": 463,
      "half-life": 464,
      "formulation affects": 465,
      "assessed": 466,
      "numb": 467,
      "storage requirement": 468,
      "route": 469,
      "spread by": 470,
      "\u6c34\u89e3": 471,
      "takes": 472,
      "subclass of": 473,
      "screens for": 474,
      "photosensitizing agents": 475,
      "originates in": 476,
      "delivered via": 477,
      "needed with": 478,
      "surveillance": 479,
      "may strengthen": 480,
      "post-marketing surveillance": 481,
      "irritates": 482,
      "detected by": 483,
      "contraindicates": 484,
      "strongly block": 485,
      "accumulates in": 486,
      "defined as": 487,
      "has half-life": 488,
      "mimics": 489,
      "are more": 490,
      "metabolizes to": 491,
      "application route": 492,
      "alternative in": 493,
      "potent": 494,
      "may be": 495,
      "drug holiday": 496,
      "reactivates": 497,
      "performed by": 498,
      "pediatric use": 499,
      "discontinuation": 500,
      "resistance mediated by": 501,
      "exposes": 502,
      "may mitigate": 503,
      "compliance issue": 504,
      "improved with": 505,
      "relaxation": 506,
      "treated by": 507,
      "molecular weight": 508,
      "a symptom of": 509,
      "includes": 510,
      "suppressed by": 511,
      "classification": 512,
      "easier to": 513,
      "mask symptoms of": 514,
      "break down into": 515,
      "confirmed by": 516,
      "approved by": 517,
      "pregnancy risk": 518,
      "excess causes": 519,
      "carries": 520,
      "adds benefits to": 521,
      "prepares": 522,
      "is stored in": 523,
      "target level": 524,
      "targeted by": 525,
      "based on": 526,
      "combine with": 527,
      "absorbs through": 528,
      "changes": 529,
      "transcribed from": 530,
      "common brand": 531,
      "endemic in": 532,
      "alternative administration": 533,
      "excipients": 534,
      "renal dose adjustment": 535,
      "subject to": 536,
      "face": 537,
      "innervates": 538,
      "mimic": 539,
      "\u6cbb\u7597": 540,
      "high doses can": 541,
      "active period of": 542,
      "important for": 543,
      "\u53ef\u7528\u4e8e": 544,
      "mitigates": 545,
      "secretion increases during": 546,
      "dilate": 547,
      "weighs about": 548,
      "accelerates": 549,
      "written by": 550,
      "result of": 551,
      "increases sensitivity to": 552,
      "FDA approval": 553,
      "advances through": 554,
      "limits": 555,
      "absorption": 556,
      "mortality rate": 557,
      "conserve": 558,
      "packaged in": 559,
      "is produced by": 560,
      "lasts": 561,
      "analyze": 562,
      "regulated by": 563,
      "examined by": 564,
      "selected by": 565,
      "pediatric dosing": 566,
      "source": 567,
      "not used in": 568,
      "popular in": 569,
      "nicknamed": 570,
      "pH level": 571,
      "beneficial for": 572,
      "deters": 573,
      "dispensed by": 574,
      "\u53ef\u80fd\u4ea7\u751f": 575,
      "now have": 576,
      "treats": 577,
      "controversial due": 578,
      "not absorbed": 579,
      "enables": 580,
      "tested in": 581,
      "secretes": 582,
      "may be affected by": 583,
      "connected to": 584,
      "can be used": 585,
      "may fail": 586,
      "visualize": 587,
      "become": 588,
      "shared by": 589,
      "placed in": 590,
      "affect": 591,
      "mediates": 592,
      "develop": 593,
      "strengthened by": 594,
      "raised by": 595,
      "related to": 596,
      "studied via": 597,
      "synthetic analog": 598,
      "transported by": 599,
      "insufficient for": 600,
      "contraindicated with": 601,
      "alternative form": 602,
      "do not block": 603,
      "described in": 604,
      "superior in": 605,
      "during": 606,
      "coordinated by": 607,
      "process": 608,
      "precursor to": 609,
      "overdose treatment": 610,
      "clears": 611,
      "effectiveness rate": 612,
      "adverse event reporting": 613,
      "receives blood from": 614,
      "create": 615,
      "can be treated with": 616,
      "DEA schedule": 617,
      "is complication of": 618,
      "required during": 619,
      "spread through": 620,
      "assessed by": 621,
      "modulated by": 622,
      "inactivated by": 623,
      "pharmacovigilance": 624,
      "comparative safety": 625,
      "\u7ec4\u5408": 626,
      "contraindicated": 627,
      "may help": 628,
      "repairs": 629,
      "orders": 630,
      "may improve": 631,
      "structural feature": 632,
      "degrades in": 633,
      "verifies": 634,
      "used post": 635,
      "resets": 636,
      "can worsen": 637,
      "contribute": 638,
      "overdose symptoms": 639,
      "prophylaxis": 640,
      "\u7814\u7a76": 641,
      "can be airborne": 642,
      "activation": 643,
      "act as": 644,
      "confers resistance to": 645,
      "acts as": 646,
      "is a risk of": 647,
      "sign of": 648,
      "recreational use": 649,
      "appears as": 650,
      "differ in": 651,
      "lactation": 652,
      "are less potent than": 653,
      "anti-androgenic effect": 654,
      "\u5173\u952e\u4e8e": 655,
      "triggers": 656,
      "outweighs": 657,
      "ablated by": 658,
      "depends on": 659,
      "synthesized from": 660,
      "concern with": 661,
      "combinations include": 662,
      "surpasses": 663,
      "inserted with": 664,
      "work with": 665,
      "don't treat": 666,
      "possesses": 667,
      "studied for": 668,
      "causes": 669,
      "disturb": 670,
      "\u7531": 671,
      "ongoing for": 672,
      "potential side effect": 673,
      "withdrawal syndrome": 674,
      "forms during": 675,
      "synergistic effect": 676,
      "advises": 677,
      "accelerated in": 678,
      "developed in": 679,
      "located above": 680,
      "spreads": 681,
      "stands for": 682,
      "occurs after": 683,
      "gives rise to": 684,
      "lines": 685,
      "neurohormonal effects": 686,
      "driven by": 687,
      "elevate": 688,
      "issues": 689,
      "sustains": 690,
      "propagate along": 691,
      "has analogue": 692,
      "expose patients to": 693,
      "\u7a7f\u8fc7": 694,
      "inhibited by": 695,
      "may benefit": 696,
      "mutation": 697,
      "insurance coverage": 698,
      "contains": 699,
      "transmitted by": 700,
      "success rate": 701,
      "kill microorganisms": 702,
      "common side effect of": 703,
      "commonly use": 704,
      "obtained from": 705,
      "used as": 706,
      "shown by": 707,
      "requires caution with": 708,
      "storage condition": 709,
      "interacts with": 710,
      "\u51b3\u5b9a": 711,
      "stores": 712,
      "checks for": 713,
      "secreted by": 714,
      "interferes with": 715,
      "interprets": 716,
      "discussed in": 717,
      "measurement units": 718,
      "may be from": 719,
      "verify": 720,
      "supplemented with": 721,
      "checks": 722,
      "lined with": 723,
      "adsorb": 724,
      "complicate": 725,
      "may relieve": 726,
      "involves": 727,
      "trial use": 728,
      "pediatric dose": 729,
      "more prone": 730,
      "burden": 731,
      "allocates": 732,
      "selected based on": 733,
      "modern use": 734,
      "reach": 735,
      "closes": 736,
      "preserve": 737,
      "discontinued after": 738,
      "screen": 739,
      "enzyme cofactor": 740,
      "sample size": 741,
      "builds": 742,
      "cannot reach": 743,
      "indication for": 744,
      "restrict": 745,
      "optimizes": 746,
      "newer than": 747,
      "correlates with": 748,
      "for": 749,
      "study": 750,
      "excreted by": 751,
      "help": 752,
      "may counteract": 753,
      "degrade in": 754,
      "reduce efficacy of": 755,
      "used": 756,
      "is managed with": 757,
      "prevention": 758,
      "used by": 759,
      "alternatives": 760,
      "may occur with": 761,
      "benefit from": 762,
      "differentiated by": 763,
      "manufacture": 764,
      "examines": 765,
      "often combined with": 766,
      "at higher risk for": 767,
      "can be monitored with": 768,
      "may turn positive during": 769,
      "filter": 770,
      "necessitate": 771,
      "aging populations drive": 772,
      "\u6539\u5584": 773,
      "fund": 774,
      "is an example of": 775,
      "can be occupational": 776,
      "maps": 777,
      "can slow": 778,
      "is protected": 779,
      "\u4e0d\u7a7f\u8fc7": 780,
      "pass through": 781,
      "may have": 782,
      "threshold": 783,
      "breakthrough": 784,
      "depleted in": 785,
      "varies among": 786,
      "\u901a\u8fc7": 787,
      "works by": 788,
      "act locally": 789,
      "absorption lower in": 790,
      "provide": 791,
      "determine": 792,
      "shown with": 793,
      "neutral on": 794,
      "first-line treatment for": 795,
      "collected by": 796,
      "vary among": 797,
      "facilitate": 798,
      "less effective than": 799,
      "occurs via": 800,
      "peaks": 801,
      "precede": 802,
      "resembles": 803,
      "educated on": 804,
      "saw": 805,
      "natural alternative": 806,
      "sheds during": 807,
      "delivered to": 808,
      "\u4f9d\u636e": 809,
      "stabilize": 810,
      "is a type of": 811,
      "analog of": 812,
      "is limited to": 813,
      "enhance": 814,
      "cleaves": 815,
      "loop type": 816,
      "relieves": 817,
      "induces": 818,
      "range": 819,
      "Nobel Prize": 820,
      "duration limited by": 821,
      "justify": 822,
      "dosage": 823,
      "rare but": 824,
      "risk": 825,
      "warrants": 826,
      "deteriorates with": 827,
      "surround": 828,
      "contraindicated in": 829,
      "measurement": 830,
      "reimburses": 831,
      "less cardiotoxic than": 832,
      "lifecycle": 833,
      "severe": 834,
      "can strengthen": 835,
      "brand name": 836,
      "influence": 837,
      "tolerance": 838,
      "manifest as": 839,
      "usually": 840,
      "transport patients": 841,
      "harbors": 842,
      "consideration": 843,
      "less likely to cause": 844,
      "emerge from": 845,
      "given during": 846,
      "may sense": 847,
      "primarily activates": 848,
      "presents with": 849,
      "symptom of": 850,
      "expand": 851,
      "combination therapy with": 852,
      "educate": 853,
      "features": 854,
      "prepared in": 855,
      "decreased by": 856,
      "administered by": 857,
      "absorbed": 858,
      "alternative therapies": 859,
      "occlusion increases": 860,
      "designed by": 861,
      "\u53d1\u5c55\u6210": 862,
      "\u6548\u679c\u53d6\u51b3\u4e8e": 863,
      "can displace": 864,
      "effectiveness measured by": 865,
      "rare in": 866,
      "may contain": 867,
      "clinical trials evaluate": 868,
      "replenished by": 869,
      "are monitored in": 870,
      "have higher risk": 871,
      "pregnancy category": 872,
      "replenishes": 873,
      "assessed with": 874,
      "rare side effect": 875,
      "mitigated by": 876,
      "palliates": 877,
      "have higher": 878,
      "measured with": 879,
      "absorption higher in": 880,
      "tested with": 881,
      "measured against": 882,
      "managed with": 883,
      "metabolized to": 884,
      "limited by": 885,
      "considered in": 886,
      "are administered via": 887,
      "thickens during": 888,
      "formulation": 889,
      "tested for": 890,
      "represents": 891,
      "receives": 892,
      "biocompatibility": 893,
      "often used in": 894,
      "ensures": 895,
      "is mitigated by": 896,
      "preserved by": 897,
      "combination therapy": 898,
      "elimination half-life": 899,
      "geriatric considerations": 900,
      "alternatives include": 901,
      "consequence": 902,
      "peak time varies by": 903,
      "safe for": 904,
      "impacted by": 905,
      "duration": 906,
      "works best": 907,
      "are prone": 908,
      "subtypes": 909,
      "used on": 910,
      "recommended for": 911,
      "patient education": 912,
      "forms": 913,
      "feature of": 914,
      "transitions to": 915,
      "follow": 916,
      "risk reduced by": 917,
      "decline with": 918,
      "often cause": 919,
      "\u964d\u4f4e\u4e8e": 920,
      "research ongoing": 921,
      "performs": 922,
      "dissolve": 923,
      "reported to": 924,
      "learns": 925,
      "often": 926,
      "varies in": 927,
      "frequency depends on": 928,
      "preceded by": 929,
      "absorb": 930,
      "links": 931,
      "inactivate": 932,
      "is branch of": 933,
      "non-pharmacological support": 934,
      "formulation includes": 935,
      "hinders": 936,
      "feature": 937,
      "non-dihydropyridines": 938,
      "is crucial for": 939,
      "performed on": 940,
      "adds": 941,
      "category": 942,
      "stabilizes": 943,
      "highly contagious": 944,
      "produced in": 945,
      "displays": 946,
      "tachyphylaxis develops with": 947,
      "impairs": 948,
      "primarily affects": 949,
      "exacerbate": 950,
      "lowered by": 951,
      "active metabolite": 952,
      "lactation risk": 953,
      "can be lowered by": 954,
      "oxygenate": 955,
      "absorption rate": 956,
      "preferred for": 957,
      "excreted as": 958,
      "reveals": 959,
      "can detect": 960,
      "\u4f18\u52bf": 961,
      "contraindication due to": 962,
      "addiction possible with": 963,
      "used during": 964,
      "connects": 965,
      "\u4f8b\u5982": 966,
      "prescribed cautiously in": 967,
      "implement": 968,
      "compared in": 969,
      "is supported by": 970,
      "may occur": 971,
      "documented in": 972,
      "is severe reaction to": 973,
      "personalized medicine": 974,
      "cost": 975,
      "are bactericidal": 976,
      "are calibrated by": 977,
      "pH affects": 978,
      "renal impairment": 979,
      "often feature": 980,
      "occurs with": 981,
      "\u63a8\u8350\u7ed9": 982,
      "highlights": 983,
      "more effective for": 984,
      "alternative surgery": 985,
      "absorbed into": 986,
      "repaired by": 987,
      "prepare": 988,
      "generate": 989,
      "fluctuate with": 990,
      "avoided with": 991,
      "unaffected by": 992,
      "\u63d0\u793a": 993,
      "relieved by": 994,
      "can treat": 995,
      "is banned in": 996,
      "is measured by": 997,
      "monitor glucose with": 998,
      "show higher cross-reactivity with": 999,
      "optimized by": 1000,
      "lined by": 1001,
      "guidelines recommend": 1002,
      "can progress to": 1003,
      "basis": 1004,
      "synergize with": 1005,
      "helps diagnose": 1006,
      "can balance": 1007,
      "occurs around": 1008,
      "are based on": 1009,
      "adjust": 1010,
      "avoids": 1011,
      "slows": 1012,
      "\u53ef\u80fd\u964d\u4f4e": 1013,
      "can be tracked with": 1014,
      "flavor": 1015,
      "sensitive to": 1016,
      "dosing": 1017,
      "helps plan": 1018,
      "maintain": 1019,
      "administered in": 1020,
      "increases with": 1021,
      "should avoid": 1022,
      "reabsorbs": 1023,
      "older than": 1024,
      "reduces need for": 1025,
      "experienced in": 1026,
      "storage": 1027,
      "more potent than": 1028,
      "bind to": 1029,
      "\u6548\u679c\u53ef\u80fd": 1030,
      "discovery": 1031,
      "reversible with": 1032,
      "built through": 1033,
      "peak after": 1034,
      "allow": 1035,
      "in": 1036,
      "is derivative of": 1037,
      "excretes": 1038,
      "act": 1039,
      "are regulated as": 1040,
      "approved for": 1041,
      "screened through": 1042,
      "expires after": 1043,
      "binds": 1044,
      "packaging includes": 1045,
      "ordered by": 1046,
      "evidence": 1047,
      "justifies": 1048,
      "synthesis requires": 1049,
      "cycle through": 1050,
      "denatured by": 1051,
      "novel": 1052,
      "released in response to": 1053,
      "rising in": 1054,
      "may precipitate": 1055,
      "may suppress": 1056,
      "\u5835\u585e": 1057,
      "prescription": 1058,
      "structure contains": 1059,
      "prevented by": 1060,
      "improves": 1061,
      "are hallmark of": 1062,
      "biosynthetic precursor": 1063,
      "also known as": 1064,
      "may mask": 1065,
      "substitute for": 1066,
      "drug of choice": 1067,
      "may interfere": 1068,
      "developed as": 1069,
      "dilates": 1070,
      "neutralizes": 1071,
      "may enhance": 1072,
      "smooth": 1073,
      "is precursor to": 1074,
      "not recommended during": 1075,
      "fight": 1076,
      "diagnosed with": 1077,
      "required for": 1078,
      "artificially increases": 1079,
      "antagonizes": 1080,
      "depends": 1081,
      "classifies into": 1082,
      "symptoms include": 1083,
      "compound": 1084,
      "hinder": 1085,
      "excretion": 1086,
      "exclude": 1087,
      "bypass": 1088,
      "sold in": 1089,
      "avoid": 1090,
      "\u5982": 1091,
      "modulates": 1092,
      "control": 1093,
      "available in": 1094,
      "should be taken with": 1095,
      "established by": 1096,
      "\u4ee3\u8c22\u4e8e": 1097,
      "governs": 1098,
      "establish": 1099,
      "respond to": 1100,
      "monitoring requires": 1101,
      "\u907f\u514d": 1102,
      "more occlusive than": 1103,
      "may": 1104,
      "submitted by": 1105,
      "list": 1106,
      "can be managed by": 1107,
      "oral bioavailability": 1108,
      "screened via": 1109,
      "is resistant to": 1110,
      "provides prolonged": 1111,
      "overreacts to": 1112,
      "source of": 1113,
      "prevent": 1114,
      "examine": 1115,
      "resist": 1116,
      "can": 1117,
      "compare": 1118,
      "development history": 1119,
      "complications": 1120,
      "absorption enhanced by": 1121,
      "\u7ec4\u6210": 1122,
      "considered when": 1123,
      "overuse leads to": 1124,
      "synthetic version": 1125,
      "development": 1126,
      "\u662f": 1127,
      "\u7ef4\u6301": 1128,
      "alternative route": 1129,
      "are processed": 1130,
      "test": 1131,
      "marks the end": 1132,
      "application frequency": 1133,
      "are classified by": 1134,
      "is higher with": 1135,
      "essential for": 1136,
      "facilitates": 1137,
      "was an": 1138,
      "interactions": 1139,
      "major": 1140,
      "risk with": 1141,
      "protect against": 1142,
      "specializes in": 1143,
      "enabled by": 1144,
      "may be caused by": 1145,
      "is associated with": 1146,
      "progresses to": 1147,
      "\u7279\u5f81\u4e3a": 1148,
      "decreases with": 1149,
      "impaired by": 1150,
      "branches from": 1151,
      "can form": 1152,
      "remains": 1153,
      "low in": 1154,
      "principle": 1155,
      "should be stored at": 1156,
      "can be ingested": 1157,
      "pumps blood to": 1158,
      "mutated in": 1159,
      "transmitted via": 1160,
      "higher with": 1161,
      "prescription form": 1162,
      "reverses": 1163,
      "plays role": 1164,
      "toxicity": 1165,
      "oxidizes": 1166,
      "act in": 1167,
      "non-pharmacological treatment": 1168,
      "may develop": 1169,
      "carcinogenicity class": 1170,
      "activated during": 1171,
      "differ by": 1172,
      "require special": 1173,
      "has better": 1174,
      "can irritate": 1175,
      "key factor in": 1176,
      "assessed via": 1177,
      "processed into": 1178,
      "varies with": 1179,
      "processes": 1180,
      "more susceptible to": 1181,
      "come in": 1182,
      "absorption rate varies by": 1183,
      "compromised by": 1184,
      "combine": 1185,
      "marketed as": 1186,
      "viewed through": 1187,
      "is synthesized from": 1188,
      "discovered in": 1189,
      "barrier to": 1190,
      "must be": 1191,
      "shows": 1192,
      "branch into": 1193,
      "promoted by": 1194,
      "\u635f\u5bb3": 1195,
      "contributes": 1196,
      "may decrease": 1197,
      "mixed in": 1198,
      "are classified": 1199,
      "may change": 1200,
      "enter through": 1201,
      "compared with": 1202,
      "\u4f34\u6709": 1203,
      "characterized by": 1204,
      "recommended daily": 1205,
      "administer": 1206,
      "assists in": 1207,
      "obtained via": 1208,
      "degrade": 1209,
      "rises with": 1210,
      "is time for": 1211,
      "reported via": 1212,
      "\u9884\u9632\u901a\u8fc7": 1213,
      "have increased": 1214,
      "absorption inhibited by": 1215,
      "may disrupt": 1216,
      "applied to": 1217,
      "primary factor in": 1218,
      "excludes": 1219,
      "\u53ef\u80fd\u5f15\u8d77": 1220,
      "decrease": 1221,
      "\u8fd8\u5305\u62ec": 1222,
      "better treated with": 1223,
      "track": 1224,
      "gathered from": 1225,
      "administration errors": 1226,
      "are first-line treatment for": 1227,
      "detected via": 1228,
      "\u66ff\u4ee3": 1229,
      "observed in": 1230,
      "composition": 1231,
      "administered via": 1232,
      "shortens": 1233,
      "disputed by": 1234,
      "are prohibited in": 1235,
      "increases levels of": 1236,
      "starts working": 1237,
      "reduced in": 1238,
      "triggered by": 1239,
      "more effective": 1240,
      "systemic effects possible with": 1241,
      "lose": 1242,
      "goal of": 1243,
      "can be": 1244,
      "lower in": 1245,
      "generated by": 1246,
      "progress to": 1247,
      "limit": 1248,
      "aim": 1249,
      "deficiency common in": 1250,
      "injected by": 1251,
      "more susceptible": 1252,
      "storage form": 1253,
      "measured in": 1254,
      "function": 1255,
      "overuse causes": 1256,
      "may contraindicate": 1257,
      "varies": 1258,
      "research target": 1259,
      "constrict": 1260,
      "concern for": 1261,
      "nutrient": 1262,
      "are subclass of": 1263,
      "research topic": 1264,
      "incur": 1265,
      "affected by": 1266,
      "is prototype of": 1267,
      "distributed via": 1268,
      "recommended by": 1269,
      "off-label use": 1270,
      "\u8868\u73b0\u4e3a": 1271,
      "fluctuate during": 1272,
      "illustrate": 1273,
      "pathway inhibited by": 1274,
      "imbalance causes": 1275,
      "guidelines in": 1276,
      "minimize": 1277,
      "showed": 1278,
      "modeled via": 1279,
      "sometimes used for": 1280,
      "strengthen": 1281,
      "have reduced": 1282,
      "preferred": 1283,
      "\u76ee\u7684\u4e3a": 1284,
      "prescriber": 1285,
      "predict": 1286,
      "improves with": 1287,
      "newer option": 1288,
      "cause": 1289,
      "developed after": 1290,
      "incompatible with": 1291,
      "converted to": 1292,
      "operate": 1293,
      "tracked in": 1294,
      "growth": 1295,
      "can involve": 1296,
      "appears hyperintense on": 1297,
      "highlight": 1298,
      "detection window": 1299,
      "more expensive than": 1300,
      "protect": 1301,
      "accelerated by": 1302,
      "evaluated in": 1303,
      "misalignment": 1304,
      "normal range": 1305,
      "requires high-dose": 1306,
      "abused by": 1307,
      "communicate via": 1308,
      "threatens": 1309,
      "can degrade": 1310,
      "more sensitive than": 1311,
      "therapy": 1312,
      "processed in": 1313,
      "surrounded by": 1314,
      "carry": 1315,
      "solubility": 1316,
      "is common side effect of": 1317,
      "dormant form": 1318,
      "treatment success": 1319,
      "work": 1320,
      "progression": 1321,
      "\u5305\u62ec": 1322,
      "aims to": 1323,
      "identified by": 1324,
      "analyzed in": 1325,
      "feed": 1326,
      "is planned using": 1327,
      "should monitor": 1328,
      "reduced by": 1329,
      "convert to": 1330,
      "include": 1331,
      "synergizes with": 1332,
      "may necessitate": 1333,
      "combination products include": 1334,
      "conducted by": 1335,
      "remain": 1336,
      "increases effect of": 1337,
      "\u5173\u8054\u4e8e": 1338,
      "protects against": 1339,
      "have anti-inflammatory properties": 1340,
      "graded by": 1341,
      "not at risk": 1342,
      "discontinued via": 1343,
      "example": 1344,
      "are a type of": 1345,
      "collaborates with": 1346,
      "complicates": 1347,
      "combines with": 1348,
      "quality checked by": 1349,
      "classified as": 1350,
      "opposes": 1351,
      "chemical formula": 1352,
      "cushions": 1353,
      "common after": 1354,
      "metabolized via": 1355,
      "slowed by": 1356,
      "address": 1357,
      "\u8bca\u65ad\u901a\u8fc7": 1358,
      "decreases effectiveness of": 1359,
      "originate from": 1360,
      "higher risk of": 1361,
      "degrade under": 1362,
      "can impair": 1363,
      "tested via": 1364,
      "tapered to avoid": 1365,
      "allows": 1366,
      "classified into": 1367,
      "should be avoided before": 1368,
      "sometimes given": 1369,
      "autoimmune": 1370,
      "toxicity treated with": 1371,
      "toxicity increased by": 1372,
      "absorbed in": 1373,
      "fast-acting for": 1374,
      "\u6cbb\u7597\u76ee\u6807": 1375,
      "help with": 1376,
      "combination": 1377,
      "burns": 1378,
      "prioritized in": 1379,
      "FDA-approved for": 1380,
      "provided by": 1381,
      "stored as": 1382,
      "\u50a8\u5b58\u4e8e": 1383,
      "relieve": 1384,
      "penetrate tissues": 1385,
      "corrected by": 1386,
      "\u52a0\u91cd": 1387,
      "sometimes require": 1388,
      "employ": 1389,
      "add vasodilation to": 1390,
      "terminate in": 1391,
      "reacts to": 1392,
      "have more": 1393,
      "explain": 1394,
      "basis of": 1395,
      "more affordable": 1396,
      "can damage": 1397,
      "date to": 1398,
      "causes resistance to": 1399,
      "may damage": 1400,
      "visible in": 1401,
      "regulates": 1402,
      "gives": 1403,
      "require modified": 1404,
      "primarily prevents": 1405,
      "favorable for": 1406,
      "generic versions available for": 1407,
      "laboratory interactions": 1408,
      "absorbed through": 1409,
      "\u7814\u7a76\u7528\u4e8e": 1410,
      "timeframe": 1411,
      "convenient": 1412,
      "classify": 1413,
      "subclassified into": 1414,
      "allows for": 1415,
      "reported in": 1416,
      "overgrowth from": 1417,
      "evaluated through": 1418,
      "emphasizes": 1419,
      "changed by": 1420,
      "detects": 1421,
      "preventable by": 1422,
      "needed for": 1423,
      "osmolality": 1424,
      "rapidly restores": 1425,
      "may mutate": 1426,
      "first generation": 1427,
      "route of administration": 1428,
      "resistance": 1429,
      "visualizes": 1430,
      "occur during": 1431,
      "now include": 1432,
      "application": 1433,
      "\u53d7\u635f\u4e8e": 1434,
      "tracked via": 1435,
      "most common": 1436,
      "raises": 1437,
      "marked": 1438,
      "increases": 1439,
      "resistance in": 1440,
      "deficiency risk in": 1441,
      "warning": 1442,
      "penetrates": 1443,
      "compliance issues": 1444,
      "contracted by": 1445,
      "are typically": 1446,
      "more accessible than": 1447,
      "enforces": 1448,
      "\u63d0\u9ad8": 1449,
      "overexpressed in": 1450,
      "monitoring needed": 1451,
      "disposal requires": 1452,
      "quantify": 1453,
      "consists of": 1454,
      "compatible with": 1455,
      "cost-effectiveness": 1456,
      "vector for": 1457,
      "thiazide type": 1458,
      "possible with": 1459,
      "adsorption depends on": 1460,
      "diagnostic aid": 1461,
      "degenerates in": 1462,
      "cross blood-brain barrier": 1463,
      "resists": 1464,
      "reveal": 1465,
      "given by": 1466,
      "tracked during": 1467,
      "evolve": 1468,
      "have fewer": 1469,
      "manage": 1470,
      "assessment": 1471,
      "visible as": 1472,
      "combination with": 1473,
      "resistance prevalence": 1474,
      "misfolding causes": 1475,
      "can impact": 1476,
      "erode": 1477,
      "shorter with": 1478,
      "schedule": 1479,
      "interaction": 1480,
      "need lower": 1481,
      "hepatic adjustment": 1482,
      "may not protect": 1483,
      "\u6740\u706d": 1484,
      "absorption reduced by": 1485,
      "belongs to": 1486,
      "eliminates": 1487,
      "assist": 1488,
      "formed by": 1489,
      "easy to": 1490,
      "inform": 1491,
      "potency": 1492,
      "are risk of": 1493,
      "helps reduce": 1494,
      "regulate": 1495,
      "may need": 1496,
      "help regulate": 1497,
      "inserted in": 1498,
      "worsened by": 1499,
      "circulates in": 1500,
      "pierced by": 1501,
      "raise": 1502,
      "coats": 1503,
      "bind": 1504,
      "measured as": 1505,
      "cleared via": 1506,
      "involved in": 1507,
      "minimal with": 1508,
      "onset of action": 1509,
      "easier to apply than": 1510,
      "metabolized by": 1511,
      "can be caused by": 1512,
      "dictates": 1513,
      "cost depends on": 1514,
      "sought from": 1515,
      "applied as": 1516,
      "benefit": 1517,
      "obstructed by": 1518,
      "is typical": 1519,
      "associates with": 1520,
      "administration route": 1521,
      "damaged by": 1522,
      "comes in": 1523,
      "expel": 1524,
      "may support": 1525,
      "can be detected by": 1526,
      "reversed by": 1527,
      "rarely metastasizes": 1528,
      "travels through": 1529,
      "off-label uses": 1530,
      "has symptom": 1531,
      "do not spread": 1532,
      "\u8bc4\u4ef7\u6807\u51c6": 1533,
      "storage protection": 1534,
      "necessary for": 1535,
      "suit": 1536,
      "develops from": 1537,
      "originate in": 1538,
      "degrades": 1539,
      "declines": 1540,
      "metabolize drugs": 1541,
      "overdose risk": 1542,
      "should be avoided": 1543,
      "take": 1544,
      "achieved with": 1545,
      "deepen": 1546,
      "risk includes": 1547,
      "costs": 1548,
      "carries risk of": 1549,
      "clinical trial": 1550,
      "eliminated via": 1551,
      "provided in": 1552,
      "absent in": 1553,
      "is regulated by": 1554,
      "elevated in": 1555,
      "diminish": 1556,
      "is rare side effect of": 1557,
      "disrupted by": 1558,
      "more effective at": 1559,
      "side effect": 1560,
      "can alter": 1561,
      "may manifest as": 1562,
      "concerning in": 1563,
      "may result in": 1564,
      "converts": 1565,
      "dose": 1566,
      "published in": 1567,
      "transported via": 1568,
      "prescribed as": 1569,
      "is both": 1570,
      "granted after": 1571,
      "\u4e3b\u8981\u4e3a": 1572,
      "filled at": 1573,
      "key enzyme": 1574,
      "comparison": 1575,
      "can cause": 1576,
      "covered by": 1577,
      "persist in": 1578,
      "can replace": 1579,
      "can be used by": 1580,
      "brand": 1581,
      "topical forms": 1582,
      "collects": 1583,
      "restricts": 1584,
      "prioritizes": 1585,
      "partition coefficient affects": 1586,
      "prophylaxis use": 1587,
      "overdose symptom": 1588,
      "displaced in": 1589,
      "classified via": 1590,
      "may seek": 1591,
      "maintains": 1592,
      "geriatric use": 1593,
      "occurs during": 1594,
      "effectiveness": 1595,
      "treat": 1596,
      "adherence issues": 1597,
      "allows use in": 1598,
      "slow": 1599,
      "patent": 1600,
      "crucial in": 1601,
      "ranges from": 1602,
      "patent expiration": 1603,
      "OTC status": 1604,
      "often need": 1605,
      "expels": 1606,
      "may prevent": 1607,
      "research area": 1608,
      "\u5305\u542b": 1609,
      "recognized by": 1610,
      "compensate for": 1611,
      "approval": 1612,
      "clinical trials": 1613,
      "used off-label": 1614,
      "similar to": 1615,
      "historical use": 1616,
      "rely on": 1617,
      "symptoms of toxicity": 1618,
      "displacement reactions": 1619,
      "concerns": 1620,
      "advised": 1621,
      "complement": 1622,
      "help in": 1623,
      "\u4f5c\u7528\u673a\u5236": 1624,
      "disrupt": 1625,
      "\u5206\u4e3a": 1626,
      "withdrawal requires": 1627,
      "consider": 1628,
      "density": 1629,
      "association with": 1630,
      "arises from": 1631,
      "ratio": 1632,
      "combined with": 1633,
      "differs between": 1634,
      "help prevent": 1635,
      "works synergistically with": 1636,
      "avoid in": 1637,
      "optimize": 1638,
      "first-line for": 1639,
      "destroys": 1640,
      "help reduce": 1641,
      "is assessed": 1642,
      "symptom is": 1643,
      "changed regularly": 1644,
      "measures about": 1645,
      "identifies": 1646,
      "taken as": 1647,
      "coenzyme for": 1648,
      "spectrum": 1649,
      "result from": 1650,
      "chemical stability": 1651,
      "can transmit": 1652,
      "vehicle affects": 1653,
      "listed on": 1654,
      "\u5ef6\u7f13": 1655,
      "a type of": 1656,
      "ensure": 1657,
      "effect": 1658,
      "defends against": 1659,
      "risks": 1660,
      "is important": 1661,
      "is reduced by": 1662,
      "elevation": 1663,
      "pose": 1664,
      "are metabolized by": 1665,
      "taught in": 1666,
      "shield": 1667,
      "are applied": 1668,
      "dosage varies by": 1669,
      "develops": 1670,
      "is a": 1671,
      "first dose effect": 1672,
      "generic versions": 1673,
      "long-acting": 1674,
      "potential": 1675,
      "form": 1676,
      "ranges": 1677,
      "research focuses on": 1678,
      "develops resistance to": 1679,
      "offers": 1680,
      "\u8003\u8651": 1681,
      "are guided by": 1682,
      "funded by": 1683,
      "leaves": 1684,
      "matters for": 1685,
      "stability affected by": 1686,
      "\u5f62\u6210": 1687,
      "releases": 1688,
      "are used for": 1689,
      "may bind": 1690,
      "complication of": 1691,
      "loosen": 1692,
      "\u76d1\u6d4b\u901a\u8fc7": 1693,
      "aims": 1694,
      "achieve": 1695,
      "\u5bfc\u81f4": 1696,
      "applied via": 1697,
      "empowers": 1698,
      "function affects": 1699,
      "document": 1700,
      "aid": 1701,
      "differentiates": 1702,
      "transfers": 1703,
      "highest in": 1704,
      "form from": 1705,
      "may secrete": 1706,
      "attack": 1707,
      "building blocks of": 1708,
      "\u589e\u5f3a": 1709,
      "brand names include": 1710,
      "advise": 1711,
      "delays excretion of": 1712,
      "research studies": 1713,
      "encourage": 1714,
      "suitable for": 1715,
      "enhance effects of": 1716,
      "\u53ef\u80fd\u5f62\u6210": 1717,
      "impact": 1718,
      "dispense": 1719,
      "sterilized by": 1720,
      "may increase": 1721,
      "prescription required": 1722,
      "differ from": 1723,
      "do not affect": 1724,
      "production decreases with": 1725,
      "move": 1726,
      "reimbursed by": 1727,
      "receptor affinity": 1728,
      "\u8054\u5408\u4f7f\u7528": 1729,
      "shape": 1730,
      "help balance": 1731,
      "conduct": 1732,
      "can cross": 1733,
      "\u7528\u4e8e\u6cbb\u7597": 1734,
      "stage": 1735,
      "altered by": 1736,
      "administrated via": 1737,
      "may take": 1738,
      "disrupted in": 1739,
      "sometimes needs": 1740,
      "first approved": 1741,
      "manages": 1742,
      "improved by": 1743,
      "important": 1744,
      "listed in": 1745,
      "attacks": 1746,
      "support": 1747,
      "first-line": 1748,
      "can be perennial": 1749,
      "lactation caution": 1750,
      "combined in": 1751,
      "contributes to": 1752,
      "have elevated": 1753,
      "superior to": 1754,
      "may have reduced efficacy with": 1755,
      "recycles": 1756,
      "converted by": 1757,
      "may protect against": 1758,
      "harm": 1759,
      "often have": 1760,
      "nourish": 1761,
      "\u5177\u6709": 1762,
      "tracked by": 1763,
      "maximizes": 1764,
      "dry": 1765,
      "degraded by": 1766,
      "removes": 1767,
      "onset": 1768,
      "cofactor for": 1769,
      "increases risk of": 1770,
      "assessed in": 1771,
      "reported with": 1772,
      "instrument": 1773,
      "narrow": 1774,
      "worsens": 1775,
      "distributed by": 1776,
      "\u53ef\u80fd\u5bfc\u81f4": 1777,
      "prioritize": 1778,
      "protein-bound in": 1779,
      "inserted under": 1780,
      "\u5b58\u5728": 1781,
      "withdrawn due to": 1782,
      "appears at": 1783,
      "salt form": 1784,
      "sometimes help": 1785,
      "tolerance develops with": 1786,
      "peer-reviewed by": 1787,
      "measured before": 1788,
      "uses": 1789,
      "associated with": 1790,
      "subdivided into": 1791,
      "among": 1792,
      "can exacerbate": 1793,
      "controlled by": 1794,
      "prescription required for": 1795,
      "more common with": 1796,
      "requires monitoring of": 1797,
      "penetration": 1798,
      "phase": 1799,
      "sometimes contains": 1800,
      "validate": 1801,
      "may lead": 1802,
      "soothe": 1803,
      "patent expired": 1804,
      "map": 1805,
      "sometimes lacks": 1806,
      "can provide": 1807,
      "occur in": 1808,
      "accessed via": 1809,
      "\u57fa\u4e8e": 1810,
      "brand names": 1811,
      "screened for": 1812,
      "avoid with": 1813,
      "monitor": 1814,
      "is linked to": 1815,
      "second-line for": 1816,
      "\u51cf\u6162\u4e8e": 1817,
      "may be mitigated by": 1818,
      "synonym for": 1819,
      "also targets": 1820,
      "overdose causes": 1821,
      "\u53ef\u80fd\u4e0e": 1822,
      "receives input": 1823,
      "blocks": 1824,
      "released during": 1825,
      "cost varies by": 1826,
      "degradation product": 1827,
      "aggravated by": 1828,
      "biomarker for": 1829,
      "enable": 1830,
      "released by": 1831,
      "dilute": 1832,
      "dilutes": 1833,
      "aids": 1834,
      "typically": 1835,
      "indications": 1836,
      "at risk for": 1837,
      "discovered by": 1838,
      "challenge": 1839,
      "can aggravate": 1840,
      "first-line therapy for": 1841,
      "unsafe during": 1842,
      "metabolize": 1843,
      "more prone to": 1844,
      "validates": 1845,
      "found in": 1846,
      "is near": 1847,
      "\u5206\u7ea7\u4e8e": 1848,
      "administration method": 1849,
      "timing": 1850,
      "suggest": 1851,
      "may slow": 1852,
      "levels rise during": 1853,
      "emergency": 1854,
      "supply chain": 1855,
      "may originate from": 1856,
      "attached to": 1857,
      "administration": 1858,
      "lasts longer": 1859,
      "enzyme target": 1860,
      "restored by": 1861,
      "brand competition": 1862,
      "remove": 1863,
      "moisturize": 1864,
      "enhances": 1865,
      "effective against": 1866,
      "is based on": 1867,
      "evaluates": 1868,
      "can improve": 1869,
      "\u76d1\u6d4b": 1870,
      "milestone for": 1871,
      "performed using": 1872,
      "pharmacokinetics": 1873,
      "involved": 1874,
      "may alter": 1875,
      "ineffective in": 1876,
      "resorb": 1877,
      "reported for": 1878,
      "collected via": 1879,
      "aims for": 1880,
      "determined by": 1881,
      "education": 1882,
      "is active": 1883,
      "mechanism differs from": 1884,
      "most deadly": 1885,
      "can suppress": 1886,
      "available without": 1887,
      "was a": 1888,
      "enhanced by": 1889,
      "optimal for": 1890,
      "reduce": 1891,
      "absorption requires": 1892,
      "protein binding": 1893,
      "store at": 1894,
      "modify": 1895,
      "sensitize": 1896,
      "funding": 1897,
      "infected by": 1898,
      "\u5bf9": 1899,
      "can predict": 1900,
      "effective for": 1901,
      "achieved via": 1902,
      "preferred by": 1903,
      "helps prevent": 1904,
      "researched by": 1905,
      "inhibits": 1906,
      "not a": 1907,
      "must comply": 1908,
      "dispenses": 1909,
      "impedes": 1910,
      "levels increase during": 1911,
      "displaces": 1912,
      "estimates": 1913,
      "check for": 1914,
      "teratogenicity": 1915,
      "neutralized by": 1916,
      "created using": 1917,
      "rehabilitation": 1918,
      "subclass": 1919,
      "identified through": 1920,
      "delivered by": 1921,
      "compares": 1922,
      "competes with": 1923,
      "synthesis": 1924,
      "mitigated with": 1925,
      "treatment": 1926,
      "used with caution with": 1927,
      "may form": 1928,
      "completed by": 1929,
      "\u9884\u9632": 1930,
      "often has": 1931,
      "absorption decreases with": 1932,
      "adjust for": 1933,
      "hydrates": 1934,
      "secretion follows": 1935,
      "assess": 1936,
      "broken down by": 1937,
      "adherence tool": 1938,
      "often prescribed with": 1939,
      "combated by": 1940,
      "symptoms": 1941,
      "disadvantage": 1942,
      "accumulate in": 1943,
      "modulate": 1944,
      "declines with": 1945,
      "preparation": 1946,
      "assessment tool": 1947,
      "prolong": 1948,
      "investigated for": 1949,
      "\u4e2a\u4f53\u5dee\u5f02": 1950,
      "optimized for": 1951,
      "may trigger": 1952,
      "taken by": 1953,
      "detect": 1954,
      "high risk of": 1955,
      "animal models use": 1956,
      "appears on": 1957,
      "reserved for": 1958,
      "are studied via": 1959,
      "limited to": 1960,
      "recommended dose": 1961,
      "promote": 1962,
      "corrects": 1963,
      "designed for": 1964,
      "bioequivalence": 1965,
      "begins at": 1966,
      "\u8bc4\u4f30\u901a\u8fc7": 1967,
      "monitor closely": 1968,
      "alternative treatments": 1969,
      "are studied in": 1970,
      "is evaluated in": 1971,
      "monitoring includes": 1972,
      "may ease": 1973,
      "diagnose": 1974,
      "directs": 1975,
      "often high in": 1976,
      "exhibit": 1977,
      "history": 1978,
      "mediate": 1979,
      "supplement": 1980,
      "exfoliates": 1981,
      "used with": 1982,
      "calculation": 1983,
      "important in": 1984,
      "diagnosis": 1985,
      "concentration in": 1986,
      "\u907f\u514d\u4e0e": 1987,
      "mediated by": 1988,
      "recommends": 1989,
      "tests": 1990,
      "inform about": 1991,
      "oversees": 1992,
      "have less": 1993,
      "\u8868\u73b0\u5305\u62ec": 1994,
      "comes from": 1995,
      "may regenerate": 1996,
      "absorption site": 1997,
      "phases": 1998,
      "reduce absorption of": 1999,
      "signals to": 2000,
      "prevalence increases": 2001,
      "aggravate": 2002,
      "synthesizes": 2003,
      "utilizes": 2004,
      "originates from": 2005,
      "systemic effects": 2006,
      "moves": 2007,
      "calm": 2008,
      "synthetic form is": 2009,
      "alternatives to": 2010,
      "prescription requires": 2011,
      "used it for": 2012,
      "metabolizes": 2013,
      "applied by": 2014,
      "is an": 2015,
      "dependent on": 2016,
      "is": 2017,
      "not for": 2018,
      "OTC availability": 2019,
      "alters": 2020,
      "propel": 2021,
      "common": 2022,
      "tests for": 2023,
      "requires": 2024,
      "predisposes to": 2025,
      "ECG effect": 2026,
      "\u4f7f\u7528": 2027,
      "is needed for": 2028,
      "transmit": 2029,
      "receives input from": 2030,
      "follow-up": 2031,
      "type of": 2032,
      "feedback inhibits": 2033,
      "weakened in": 2034,
      "can metastasize": 2035,
      "drives": 2036,
      "initiated before": 2037,
      "often caused by": 2038,
      "excretion unchanged": 2039,
      "form in": 2040,
      "checked via": 2041,
      "association": 2042,
      "awarded by": 2043,
      "balance": 2044,
      "primary goal of": 2045,
      "is best for": 2046,
      "precursor for": 2047,
      "phosphorylates": 2048,
      "recognize": 2049,
      "train": 2050,
      "\u7981\u5fcc\u4e8e": 2051,
      "invaded by": 2052,
      "risks include": 2053,
      "mitigate": 2054,
      "stockage": 2055,
      "reproduce by": 2056,
      "categorized in": 2057,
      "indicate": 2058,
      "originally developed for": 2059,
      "relaxes": 2060,
      "cautioned about": 2061,
      "discontinuation protocol": 2062,
      "helps manage": 2063,
      "can trigger": 2064,
      "labeled with": 2065,
      "may interact": 2066,
      "specialization": 2067,
      "\u6cbb\u7597\u5305\u62ec": 2068,
      "guides": 2069,
      "increases risk": 2070,
      "enterohepatic recirculation": 2071,
      "comprise": 2072,
      "basis for": 2073,
      "research conducted by": 2074,
      "result": 2075,
      "unclog": 2076,
      "may become": 2077,
      "decreases absorption": 2078,
      "consult": 2079,
      "treatment duration": 2080,
      "protects": 2081,
      "evaluated by": 2082,
      "acidifies": 2083,
      "antagonist": 2084,
      "genetic": 2085,
      "prone to": 2086,
      "characteristic": 2087,
      "digested in": 2088,
      "distribution affected by": 2089,
      "function measured by": 2090,
      "\u7528\u4e8e": 2091,
      "have": 2092,
      "adequacy": 2093,
      "vary in": 2094,
      "active form of": 2095,
      "collected from": 2096,
      "often includes": 2097,
      "inspect": 2098,
      "supported by": 2099,
      "achieved by": 2100,
      "displace": 2101,
      "invest in": 2102,
      "less side effects": 2103,
      "is disclosed in": 2104,
      "guided by": 2105,
      "compete with": 2106,
      "is extended-spectrum": 2107,
      "results in": 2108,
      "can contraindicate": 2109,
      "\u68c0\u6d4b\u4e8e": 2110,
      "are a subclass of": 2111,
      "contraindication": 2112,
      "must be ruled out": 2113,
      "habitat": 2114,
      "exfoliate": 2115,
      "treated with": 2116,
      "distribution volume": 2117,
      "supervised by": 2118,
      "assesses": 2119,
      "patented in": 2120,
      "combat": 2121,
      "balanced against": 2122,
      "protected by": 2123,
      "hijacked by": 2124,
      "predicts": 2125,
      "activate": 2126,
      "availability": 2127,
      "may clog": 2128,
      "uncommon with": 2129,
      "sometimes use": 2130,
      "tolerate": 2131,
      "enzymes break down": 2132,
      "is unit of": 2133,
      "are preferred in": 2134,
      "benign": 2135,
      "performed via": 2136,
      "measures": 2137,
      "often requires": 2138,
      "monitored during": 2139,
      "perform": 2140,
      "prescribed based": 2141,
      "specialized": 2142,
      "\u6539\u53d8": 2143,
      "helps in": 2144,
      "requires dose adjustment of": 2145,
      "cytokine involved": 2146,
      "reviewed during": 2147,
      "depletes with": 2148,
      "taken": 2149,
      "processed by": 2150,
      "derived from": 2151,
      "scheduled via": 2152,
      "\u9776\u5411": 2153,
      "precaution": 2154,
      "\u53ef\u80fd\u8fdb\u5c55\u4e3a": 2155,
      "broader than": 2156,
      "demonstrate": 2157,
      "climate favors": 2158,
      "life cycle includes": 2159,
      "major protein of": 2160,
      "often used by": 2161,
      "\u53ef\u80fd\u6709": 2162,
      "revolutionized": 2163,
      "connects to": 2164,
      "is the": 2165,
      "blocked by": 2166,
      "worsens with": 2167,
      "organizes drugs by": 2168,
      "adjunct in": 2169,
      "adherence important": 2170,
      "restored with": 2171,
      "review": 2172,
      "can fail": 2173,
      "recalled due to": 2174,
      "activates": 2175,
      "\u4f9d\u8d56": 2176,
      "teach": 2177,
      "relates to": 2178,
      "pumps": 2179,
      "boosts": 2180,
      "can regulate": 2181,
      "effectiveness decreases": 2182,
      "passes": 2183,
      "potentiates": 2184,
      "inhabit": 2185,
      "is often": 2186,
      "coordinates": 2187,
      "monitoring needed for": 2188,
      "statistical power": 2189,
      "consist of": 2190,
      "accesses": 2191,
      "onset time": 2192,
      "work in": 2193,
      "more common in": 2194,
      "cheaper than": 2195,
      "myelinated by": 2196,
      "adjuvant use": 2197,
      "refers to": 2198,
      "temporary": 2199,
      "regulatory approval": 2200,
      "antidote": 2201,
      "potentiate": 2202,
      "not effective for": 2203,
      "help build": 2204,
      "dysfunction linked to": 2205,
      "life-threatening condition": 2206,
      "minimizes": 2207,
      "increase risk of": 2208,
      "shortage": 2209,
      "may irritate": 2210,
      "reviewed by": 2211,
      "often combined": 2212,
      "managed by": 2213,
      "does not prevent": 2214,
      "infection": 2215,
      "considered": 2216,
      "constricts": 2217,
      "followed by": 2218,
      "\u4e0e": 2219,
      "diagnostic test": 2220,
      "cost factor": 2221,
      "located below": 2222,
      "present in": 2223,
      "advise on": 2224,
      "worn by": 2225,
      "can absorb": 2226,
      "adjusted based on": 2227,
      "classified under": 2228,
      "sprayed on": 2229,
      "examples": 2230,
      "adjusts": 2231,
      "high in": 2232,
      "tolerance develops": 2233,
      "prescribed with": 2234,
      "future developments": 2235,
      "soothes": 2236,
      "dispensed in": 2237,
      "are targets of": 2238,
      "weakened by": 2239,
      "toxic at": 2240,
      "may show": 2241,
      "administered as": 2242,
      "preserves": 2243,
      "inflammation of": 2244,
      "research": 2245,
      "acts on": 2246,
      "can relieve": 2247,
      "type": 2248,
      "pH": 2249,
      "are found in": 2250,
      "pose risk of": 2251,
      "patient monitoring": 2252,
      "may involve": 2253,
      "numbs": 2254,
      "result in": 2255,
      "fights": 2256,
      "risk in": 2257,
      "build": 2258,
      "symptom": 2259,
      "should be spaced apart from": 2260,
      "especially important with": 2261,
      "is delayed by": 2262,
      "is approved for": 2263,
      "destroy": 2264,
      "benefits from": 2265,
      "main ingredient": 2266,
      "applied": 2267,
      "synergizes": 2268,
      "biomarker": 2269,
      "excreted through": 2270,
      "number varies": 2271,
      "depletes": 2272,
      "should not be": 2273,
      "printed on": 2274,
      "quality of life improves with": 2275,
      "is used for": 2276,
      "considerations": 2277,
      "tone": 2278,
      "increase risk": 2279,
      "inversely related": 2280,
      "\u5438\u5f15": 2281,
      "worsen": 2282,
      "may prolong": 2283,
      "primarily lower": 2284,
      "is a sign of": 2285,
      "levels indicate": 2286,
      "global need": 2287,
      "have lower cross-reactivity with": 2288,
      "therapeutic index": 2289,
      "can boost": 2290,
      "formulated as": 2291,
      "harms": 2292,
      "\u8bc4\u4f30": 2293,
      "rich in": 2294,
      "adherence": 2295,
      "thresholds vary by": 2296,
      "\u53ef\u5bfc\u81f4": 2297,
      "consumed by": 2298,
      "may deplete": 2299,
      "increases demand for": 2300,
      "account for": 2301,
      "delays": 2302,
      "severity depends on": 2303,
      "supplements": 2304,
      "is part of": 2305,
      "\u5728": 2306,
      "employs": 2307,
      "lasts for": 2308,
      "affects": 2309,
      "may impair": 2310,
      "set by": 2311,
      "influenced by": 2312,
      "peak effect": 2313,
      "participant": 2314,
      "work best with": 2315,
      "examined for": 2316,
      "masks": 2317,
      "can be contacted": 2318,
      "trade names": 2319,
      "\u5b9a\u4e49\u4e3a": 2320,
      "has narrow": 2321,
      "historic use": 2322,
      "drooping": 2323,
      "interact with": 2324,
      "\u8bc4\u4f30\u4e8e": 2325,
      "has different": 2326,
      "discovery year": 2327,
      "adjusted for": 2328,
      "fills": 2329,
      "contrast with": 2330,
      "despite": 2331,
      "makes": 2332,
      "\u4ea7\u751f": 2333,
      "pharmacophore": 2334,
      "develops over": 2335,
      "alleviates": 2336,
      "is influenced by": 2337,
      "act on": 2338,
      "\u91ca\u653e": 2339,
      "enter": 2340,
      "removed by": 2341,
      "updates": 2342,
      "quantifies": 2343,
      "may preserve": 2344,
      "second generation": 2345,
      "given": 2346,
      "ATC code": 2347,
      "prevalence": 2348,
      "worse in": 2349,
      "show time-dependent": 2350,
      "have immature": 2351,
      "\u4e0d\u9002\u7528\u4e8e": 2352,
      "indicates": 2353,
      "prompts": 2354,
      "restricted in": 2355,
      "adjunct to": 2356,
      "differential diagnosis": 2357,
      "available as": 2358,
      "absorption decreased by": 2359,
      "is affected by": 2360,
      "side effect of": 2361,
      "delayed by": 2362,
      "examples include": 2363,
      "is selective": 2364,
      "wears": 2365,
      "resistance caused by": 2366,
      "\u53ef\u80fd\u9884\u6d4b": 2367,
      "binds tightly to": 2368,
      "trained in": 2369,
      "evaluates by": 2370,
      "heal": 2371,
      "sometimes combined": 2372,
      "frequency of administration": 2373,
      "located in": 2374,
      "may experience": 2375,
      "less expensive than": 2376,
      "can still": 2377,
      "not for use on": 2378,
      "sequenced for": 2379,
      "claimed by": 2380,
      "targets": 2381,
      "thicken during": 2382,
      "could reduce": 2383,
      "duration depends on": 2384,
      "decrease during": 2385,
      "aim for": 2386,
      "synthesis involves": 2387,
      "distribution": 2388,
      "breakdown": 2389,
      "discovered through": 2390,
      "patent status": 2391,
      "don't reduce": 2392,
      "dialysis": 2393,
      "implanted in": 2394,
      "temporary solution": 2395,
      "supplies": 2396,
      "come as": 2397,
      "located on": 2398,
      "filters": 2399,
      "a sign of": 2400,
      "\u8c03\u8282": 2401,
      "release": 2402,
      "good for": 2403,
      "can enhance": 2404,
      "increase": 2405,
      "applies": 2406,
      "found on": 2407,
      "withdrawn gradually": 2408,
      "hazardous to": 2409,
      "component of": 2410,
      "can be seasonal": 2411,
      "toxicity symptom": 2412,
      "produced from": 2413,
      "generic version": 2414,
      "graded": 2415,
      "higher in": 2416,
      "dietary source": 2417,
      "should include": 2418,
      "eliminate": 2419,
      "spreads through": 2420,
      "conflicts with": 2421,
      "resolves": 2422,
      "subtypes include": 2423,
      "missed dose": 2424,
      "\u5f02\u5e38\u4e8e": 2425,
      "purchased by": 2426,
      "frequently need": 2427,
      "develops after": 2428,
      "show": 2429,
      "contained by": 2430,
      "achieved through": 2431,
      "wrote": 2432,
      "helps with": 2433,
      "\u91cd\u8981\u5bf9\u4e8e": 2434,
      "receive": 2435,
      "is reversible with": 2436,
      "indicated by": 2437,
      "holds": 2438,
      "potential use": 2439,
      "set": 2440,
      "has alternatives": 2441,
      "converted from": 2442,
      "mechanism similarity": 2443,
      "impaired in": 2444,
      "are building blocks of": 2445,
      "advantage": 2446,
      "has types": 2447,
      "caution": 2448,
      "supplement form": 2449,
      "may replace": 2450,
      "introduced in": 2451,
      "led to": 2452,
      "also acts as": 2453,
      "solution": 2454,
      "aims at": 2455,
      "historically called": 2456,
      "are type of": 2457,
      "complements": 2458,
      "levels peak at": 2459,
      "seek": 2460,
      "preferred over": 2461,
      "\u6e90\u4e8e": 2462,
      "is obtained from": 2463,
      "may occur due to": 2464,
      "inflames": 2465,
      "empirical therapy": 2466,
      "repels": 2467,
      "types": 2468,
      "alter": 2469,
      "is essential for": 2470,
      "excreted": 2471,
      "digested into": 2472,
      "hydrate": 2473,
      "defend against": 2474,
      "sets": 2475,
      "elimination": 2476,
      "discourages": 2477,
      "management": 2478,
      "stockpiled for": 2479,
      "not recommended for": 2480,
      "option for": 2481,
      "occurs between": 2482,
      "administrated as": 2483,
      "may appear": 2484,
      "lack": 2485,
      "may cause": 2486,
      "addresses": 2487,
      "enriched with": 2488,
      "WHO essential medicine": 2489,
      "weakens": 2490,
      "not recommended with": 2491,
      "dissolves": 2492,
      "helps identify": 2493,
      "differs from": 2494,
      "can alleviate": 2495,
      "susceptible to": 2496,
      "adjusted in": 2497,
      "mask": 2498,
      "extracted from": 2499,
      "generates": 2500,
      "convert": 2501,
      "street name": 2502,
      "break down": 2503,
      "work at": 2504,
      "traps": 2505,
      "researched for": 2506,
      "accessed by": 2507,
      "damage": 2508,
      "prepared by": 2509,
      "WHO guideline": 2510,
      "guideline": 2511,
      "recycled via": 2512,
      "research in": 2513,
      "diagnoses": 2514,
      "legal status": 2515,
      "is diagnosed": 2516,
      "facilitated by": 2517,
      "interpreted by": 2518,
      "avoided in": 2519,
      "commonly supplemented in": 2520,
      "component": 2521,
      "may interfere with": 2522,
      "decreases risk of": 2523,
      "\u6d4b\u91cf": 2524,
      "assist in": 2525,
      "means": 2526,
      "can aid": 2527,
      "metabolized into": 2528,
      "OTC available for": 2529,
      "may coexist with": 2530,
      "\u9632\u6b62": 2531,
      "not suitable for": 2532,
      "stops": 2533,
      "protect from": 2534,
      "free of": 2535,
      "innervate": 2536,
      "part of": 2537,
      "powers": 2538,
      "countered by": 2539,
      "stability in": 2540,
      "tracks": 2541,
      "governed by": 2542,
      "may worsen": 2543,
      "types include": 2544,
      "divided into": 2545,
      "prevents": 2546,
      "can interact with": 2547,
      "confined to": 2548,
      "has type": 2549,
      "magnify": 2550,
      "receive adjusted doses": 2551,
      "research focus": 2552,
      "withdrawal": 2553,
      "drug class": 2554,
      "stored in": 2555,
      "publish in": 2556,
      "\u9884\u6d4b": 2557,
      "stains": 2558,
      "symptom relief": 2559,
      "is altered in": 2560,
      "comorbid with": 2561,
      "can include": 2562,
      "used for": 2563,
      "often require": 2564,
      "appear as": 2565,
      "lazy eye": 2566,
      "clear": 2567,
      "complication": 2568,
      "also available": 2569,
      "target of": 2570,
      "terminates": 2571,
      "initiates": 2572,
      "oversee": 2573,
      "strive for": 2574,
      "cross": 2575,
      "specifies": 2576,
      "share structure with": 2577,
      "less effective for": 2578,
      "known as": 2579,
      "\u523a\u6fc0": 2580,
      "advances": 2581,
      "diagnosed by": 2582,
      "prolongation": 2583,
      "personalize": 2584,
      "\u76d1\u6d4b\u4e8e": 2585,
      "should be": 2586,
      "repositions": 2587,
      "degraded in": 2588,
      "thrive in": 2589,
      "is under": 2590,
      "constrict due to": 2591,
      "evaluated using": 2592,
      "may vary in": 2593,
      "is a symptom": 2594,
      "suggests": 2595,
      "prescriber specialty": 2596,
      "emulsify": 2597,
      "at risk of": 2598,
      "extend": 2599,
      "marketed for": 2600,
      "black box warning": 2601,
      "shows increasing": 2602,
      "can be improved by": 2603,
      "spread": 2604,
      "\u5e38\u4f34\u6709": 2605,
      "\u529f\u80fd\u8bc4\u4f30\u7528": 2606,
      "prescribed for": 2607,
      "extends": 2608,
      "approved": 2609,
      "produced as": 2610,
      "may react to": 2611,
      "vulnerable to": 2612,
      "cross placenta": 2613,
      "marketed by": 2614,
      "not applied to": 2615,
      "monitoring parameter": 2616,
      "\u4fdd\u62a4": 2617,
      "passes into": 2618,
      "can result from": 2619,
      "\u5931\u5e38\u4e8e": 2620,
      "contraindicated for": 2621,
      "determines": 2622,
      "lipid solubility": 2623,
      "asymptomatic in": 2624,
      "risk factor": 2625,
      "toxicity symptoms": 2626,
      "synthesized as": 2627,
      "provide long-term": 2628,
      "may suggest": 2629,
      "delivers drug through": 2630,
      "check": 2631,
      "depression": 2632,
      "essential": 2633,
      "also available as": 2634,
      "obstructs": 2635,
      "occurs in": 2636,
      "ranked by": 2637,
      "describes": 2638,
      "evaluated via": 2639,
      "elevates": 2640,
      "future direction": 2641,
      "bypasses": 2642,
      "tool for": 2643,
      "strengthens": 2644,
      "detectable in": 2645,
      "effective in": 2646,
      "consume": 2647,
      "monitored with": 2648,
      "evaluated": 2649,
      "valuable for": 2650,
      "timing matters": 2651,
      "covers": 2652,
      "recommended intake": 2653,
      "volume of distribution": 2654,
      "not evaluated by": 2655,
      "not effective": 2656,
      "secreted in": 2657,
      "swelling indicates": 2658,
      "fourth generation": 2659,
      "met by": 2660,
      "hypothesized via": 2661,
      "may develop into": 2662,
      "\u6291\u5236": 2663,
      "can prevent": 2664,
      "acts in": 2665,
      "\u53ef\u80fd\u7531": 2666,
      "guidelines": 2667,
      "repurposed for": 2668,
      "\u5173\u8054": 2669,
      "operated by": 2670,
      "linked to": 2671,
      "\u53ef\u80fd\u5f71\u54cd": 2672,
      "\u7814\u53d1\u6d89\u53ca": 2673,
      "indicator": 2674,
      "lactation safety": 2675,
      "increases likelihood": 2676,
      "seen on": 2677,
      "interacts": 2678,
      "require": 2679,
      "work on": 2680,
      "reverse with": 2681,
      "reactivation causes": 2682,
      "antagonized by": 2683,
      "may use": 2684,
      "undergoes": 2685,
      "secreted during": 2686,
      "lubricate": 2687,
      "may regulate": 2688,
      "may lead to": 2689,
      "recommended daily intake": 2690,
      "are used in": 2691,
      "speed up": 2692,
      "adverse events": 2693,
      "deliver to": 2694,
      "paired with": 2695,
      "staged by": 2696,
      "chemical class": 2697,
      "prefer": 2698,
      "toxicity affects": 2699,
      "crucial for": 2700,
      "primarily excreted": 2701,
      "returns to": 2702,
      "less potent than": 2703,
      "global burden": 2704,
      "mechanism of": 2705,
      "compete in": 2706,
      "attracts": 2707,
      "is antidote for": 2708,
      "often take": 2709,
      "predicted by": 2710,
      "approves": 2711,
      "relate to": 2712,
      "screening": 2713,
      "\u7ed9\u836f\u9014\u5f84": 2714,
      "receptor binding": 2715,
      "synergy": 2716,
      "travel via": 2717,
      "has side effect": 2718,
      "marker": 2719,
      "side effects include": 2720,
      "medication": 2721,
      "comprises": 2722,
      "must follow": 2723,
      "chemical structure": 2724,
      "discontinued for": 2725,
      "RELATIONSHIP": 2726,
      "may result from": 2727,
      "is a general term for": 2728,
      "used alongside": 2729,
      "applied on": 2730,
      "increases requirement for": 2731,
      "namesake": 2732,
      "not used for": 2733,
      "resistance genes": 2734,
      "disorder": 2735,
      "research use": 2736,
      "are absorbed in": 2737,
      "less side effects than": 2738,
      "resistance mechanism": 2739,
      "tailors": 2740,
      "purchased as": 2741,
      "have different": 2742,
      "acute phase reactant": 2743,
      "used postoperatively": 2744,
      "\u53cd\u6620": 2745,
      "critical for": 2746,
      "contain": 2747,
      "oral administration of": 2748,
      "depend on": 2749,
      "generic": 2750,
      "amplify": 2751,
      "may alleviate": 2752,
      "evaluated for": 2753,
      "should combine with": 2754,
      "performed for": 2755,
      "included in": 2756,
      "are subject to": 2757,
      "decreases risk": 2758,
      "limited in": 2759,
      "most common type": 2760,
      "endemic for": 2761,
      "maintained by": 2762,
      "metabolized": 2763,
      "generic available": 2764,
      "destroyed by": 2765,
      "screened with": 2766,
      "stewardship": 2767,
      "personalized via": 2768,
      "prevented via": 2769,
      "packaging": 2770,
      "restore": 2771,
      "maximum dose": 2772,
      "overuse": 2773,
      "verified through": 2774,
      "is synthetic": 2775,
      "administration technique": 2776,
      "duration varies by": 2777,
      "\u8f85\u52a9": 2778,
      "can induce": 2779,
      "needed in": 2780,
      "applied before": 2781,
      "can be separated": 2782,
      "thickens": 2783,
      "counteract": 2784,
      "easier for": 2785,
      "inflammation": 2786,
      "can lead to": 2787,
      "metabolite": 2788,
      "veterinary use": 2789,
      "severity": 2790,
      "increases inflammation": 2791,
      "a subtype of": 2792,
      "inactivated in": 2793,
      "secrete": 2794,
      "evaluation": 2795,
      "may lower": 2796,
      "dosage adjustment": 2797,
      "safer than": 2798,
      "has risk of": 2799,
      "develops with": 2800,
      "cost-effective for": 2801,
      "mix with": 2802,
      "measured via": 2803,
      "may interact with": 2804,
      "lower": 2805,
      "regulated more strictly": 2806,
      "deficiency": 2807,
      "breaks down": 2808,
      "exist in": 2809,
      "\u75c7\u72b6\u5305\u62ec": 2810,
      "filtered by": 2811,
      "threat to": 2812,
      "contraindicate": 2813,
      "increased by": 2814,
      "\u53d6\u51b3\u4e8e": 2815,
      "composed of": 2816,
      "may potentiate": 2817,
      "\u8bc6\u522b": 2818,
      "sold as": 2819,
      "are affected by": 2820,
      "\u4f5c\u7528\u4e8e": 2821,
      "damaged in": 2822,
      "collaborate on": 2823,
      "future": 2824,
      "soften": 2825,
      "opsonize": 2826,
      "typically is": 2827,
      "checked before": 2828,
      "leads": 2829,
      "calculated by": 2830,
      "can detoxify": 2831,
      "issue": 2832,
      "approve": 2833,
      "\u786e\u4fdd": 2834,
      "commonly treated with": 2835,
      "used with caution": 2836,
      "well tolerated in": 2837,
      "minimized by": 2838,
      "lasts under": 2839,
      "sometimes available": 2840,
      "class includes": 2841,
      "mutates": 2842,
      "antagonistic with": 2843,
      "storage requires": 2844,
      "also treat": 2845,
      "supports": 2846,
      "hepatic impairment": 2847,
      "has long": 2848,
      "research focus on": 2849,
      "deposit in": 2850,
      "desensitizes": 2851,
      "are detected by": 2852,
      "mechanism": 2853,
      "hallmark of": 2854,
      "drains": 2855,
      "a side effect of": 2856,
      "monitoring": 2857,
      "ensured by": 2858,
      "shed in": 2859,
      "production": 2860,
      "prescription needed": 2861,
      "visible under": 2862,
      "patient counseling": 2863,
      "link": 2864,
      "suppresses": 2865,
      "adverse effect": 2866,
      "developed through": 2867,
      "peak during": 2868,
      "need": 2869,
      "\u6307\u5bfc": 2870,
      "exchanges": 2871,
      "\u8bc4\u4f30\u7528": 2872,
      "shelf life": 2873,
      "has risks": 2874,
      "active metabolites": 2875,
      "decays to": 2876,
      "genetic variation": 2877,
      "topical use": 2878,
      "occur with": 2879,
      "can deplete": 2880,
      "must pass": 2881,
      "should not be used": 2882,
      "attract": 2883,
      "could be": 2884,
      "achieves": 2885,
      "commonly spreads to": 2886,
      "marker for": 2887,
      "manufactured by": 2888,
      "emits": 2889,
      "effect altered by": 2890,
      "broader class": 2891,
      "drug interactions": 2892,
      "used off-label for": 2893,
      "measured by": 2894,
      "lack in": 2895,
      "accessible": 2896,
      "is more": 2897,
      "creates": 2898,
      "forces out": 2899,
      "should block": 2900,
      "line": 2901,
      "name": 2902,
      "achieved for": 2903,
      "controls for": 2904,
      "transports": 2905,
      "cover": 2906,
      "block": 2907,
      "mechanism of action": 2908,
      "demonstrated in": 2909,
      "clogs": 2910,
      "is in": 2911,
      "precursor of": 2912,
      "transport": 2913,
      "investigated by": 2914,
      "corrected with": 2915,
      "monitoring required for": 2916,
      "used in": 2917,
      "diagnosed via": 2918,
      "controls": 2919,
      "bioavailability": 2920,
      "stimulate": 2921,
      "manufacturing requires": 2922,
      "need reduced": 2923,
      "\u836f\u6548\u5b66": 2924,
      "causes fluorosis at": 2925,
      "crosses BBB": 2926,
      "levels vary with": 2927,
      "poorly absorbed": 2928,
      "not mixed with": 2929,
      "deter": 2930,
      "manifests as": 2931,
      "subset of": 2932,
      "reduces absorption of": 2933,
      "hepatic dose adjustment": 2934,
      "sometimes replace": 2935,
      "read by": 2936,
      "may include": 2937,
      "analyzed by": 2938,
      "trigger": 2939,
      "at higher risk": 2940,
      "\u5e38\u89c1\u4e8e": 2941,
      "inserted into": 2942,
      "enters breast milk": 2943,
      "can be managed": 2944,
      "reflects": 2945,
      "colorants": 2946,
      "necessitates": 2947,
      "measure": 2948,
      "deficiency causes": 2949,
      "amplifies": 2950,
      "kills": 2951,
      "resistance marker": 2952,
      "less commonly used": 2953,
      "design": 2954,
      "lower risk of": 2955,
      "purpose": 2956,
      "has risk": 2957,
      "less commonly used than": 2958,
      "specify": 2959,
      "prescribed post": 2960,
      "transport protein": 2961,
      "catalyzes": 2962,
      "temperature": 2963,
      "\u51cf\u5c11": 2964,
      "are effective against": 2965,
      "duration of action": 2966,
      "contraindication for": 2967,
      "carry risk of": 2968,
      "safety": 2969,
      "prescribing trends show": 2970,
      "receptor target": 2971,
      "monitored in": 2972,
      "absorption varies by": 2973,
      "gold standard": 2974,
      "heal faster with": 2975,
      "expiration": 2976,
      "require no": 2977,
      "common in": 2978,
      "combats": 2979,
      "development involves": 2980,
      "replaced by": 2981,
      "cleared by": 2982,
      "accelerate": 2983,
      "role": 2984,
      "metabolism": 2985,
      "distribution involves": 2986,
      "metabolized in": 2987,
      "polymer of": 2988,
      "precedes": 2989,
      "specializes": 2990,
      "alternative treatment": 2991,
      "attaches to": 2992,
      "alleviate": 2993,
      "abused as": 2994,
      "potency determined by": 2995,
      "\u88ab\u6291\u5236\u5bfc\u81f4": 2996,
      "environmental risk": 2997,
      "modified by": 2998,
      "regenerate via": 2999,
      "offer": 3000,
      "such as": 3001,
      "detected in": 3002,
      "leads to": 3003,
      "research ongoing for": 3004,
      "neutral effect on": 3005,
      "modifies": 3006,
      "transforms": 3007,
      "synthesized by": 3008,
      "implemented by": 3009,
      "material": 3010,
      "softens": 3011,
      "overdosed": 3012,
      "may target": 3013,
      "guideline recommendation": 3014,
      "weaker than": 3015,
      "contracts": 3016,
      "repair": 3017,
      "has effect": 3018,
      "underlie": 3019,
      "cleanse": 3020,
      "are reported to": 3021,
      "belong to": 3022,
      "customized for": 3023,
      "are researched for": 3024,
      "lowers": 3025,
      "presented by": 3026,
      "is when": 3027,
      "implicated in": 3028,
      "site of": 3029,
      "specialist in": 3030,
      "responds to": 3031,
      "minimal for": 3032,
      "is used in": 3033,
      "called": 3034,
      "does not block": 3035,
      "less effective in": 3036,
      "conducted in": 3037,
      "helps": 3038,
      "correlates": 3039,
      "monitored through": 3040,
      "work via": 3041,
      "heals around": 3042,
      "treatment for": 3043,
      "adverse effects correlate with": 3044,
      "withdrawal symptom": 3045,
      "adapt to": 3046,
      "enters": 3047,
      "compensates": 3048,
      "hospital use": 3049,
      "studies": 3050,
      "needs": 3051,
      "is important for": 3052,
      "dosed by": 3053,
      "often needs": 3054,
      "from": 3055,
      "enforced by": 3056,
      "absorption affected by": 3057,
      "comparative efficacy": 3058,
      "dosage depends on": 3059,
      "occurs due to": 3060,
      "first-line treatment": 3061,
      "may reduce": 3062,
      "circulate in": 3063,
      "manufacturer": 3064,
      "increase indicates": 3065,
      "required by": 3066,
      "\u901a\u5e38": 3067,
      "vary by": 3068,
      "alternative": 3069,
      "thins": 3070,
      "may require": 3071,
      "differentiate into": 3072,
      "suppress": 3073,
      "genetic regulation": 3074,
      "rarely cause": 3075,
      "stronger than": 3076,
      "influences": 3077,
      "issued by": 3078,
      "detected with": 3079,
      "prevented with": 3080,
      "role in": 3081,
      "cool": 3082,
      "expiration date": 3083,
      "utilize": 3084,
      "excretion route": 3085,
      "can increase": 3086,
      "analyzes": 3087,
      "meta-analysis shows": 3088,
      "renal adjustment": 3089,
      "may help with": 3090,
      "results from": 3091,
      "rebound phenomenon occurs after": 3092,
      "relies on": 3093,
      "category includes": 3094,
      "often susceptible to": 3095,
      "\u53ef\u4ee5": 3096,
      "can be mixed": 3097,
      "due to": 3098,
      "helps regulate": 3099,
      "laboratory interference": 3100,
      "standardize": 3101,
      "dosed": 3102,
      "treatment for toxicity": 3103,
      "evaluate": 3104,
      "is called": 3105,
      "worked on": 3106,
      "may affect": 3107,
      "works best at": 3108,
      "produce": 3109,
      "mediator": 3110,
      "sometimes cause": 3111,
      "incorporate": 3112,
      "loosens": 3113,
      "researched in": 3114,
      "obtained at": 3115,
      "can provoke": 3116,
      "fertilizes": 3117,
      "reflect": 3118,
      "store": 3119,
      "helps evaluate": 3120,
      "antagonize": 3121,
      "emit": 3122,
      "other class": 3123,
      "helps cope with": 3124,
      "alternative approach": 3125,
      "cloud": 3126,
      "indicator of": 3127,
      "caution in": 3128,
      "converts to": 3129,
      "examples are": 3130,
      "excretion half-life": 3131,
      "\u53d7": 3132,
      "deposits": 3133,
      "comorbidity": 3134,
      "\u5408\u6210\u9700\u8981": 3135,
      "boost": 3136,
      "\u6392\u6cc4\u4e8e": 3137,
      "scheduled by": 3138,
      "may exclude": 3139,
      "can spread": 3140,
      "vital for": 3141,
      "collaborate with": 3142,
      "\u63a7\u5236": 3143,
      "involve": 3144,
      "approach": 3145,
      "follows": 3146,
      "stability": 3147,
      "infect": 3148,
      "distributes": 3149,
      "delay": 3150,
      "peaks at": 3151,
      "dysregulated in": 3152,
      "deliver": 3153,
      "\u4ee3\u8868\u836f\u7269": 3154,
      "aids in": 3155,
      "prepares for": 3156,
      "improve": 3157,
      "administration timing": 3158,
      "techniques include": 3159
}